Market Data
Market Cap₹2,286.96 Cr.
52W High₹2,043.15
Current Price₹1,710.9
52W Low₹423.7
Down from 52W High16.3 %
Face Value₹10
Performance
ROCE22.43 %
ROE17.5 %
EPS (TTM)₹17.18
EPS Prev Qtr₹35.53
EPS Last Year₹15.06
EBITDA Qtr₹27.42 Cr.
Book Value₹496
Financial Health
Debt/Equity0.02
Debt/Profit0.11
Total Assets₹853.7 Cr.
Dividend Yield0.58 %
Promoter Holding41.76 %
Earning Power16.38 %
Valuation
Stock P/E19.69
Industry P/E33.3
Price to Book3.45
Price to Sales2.82
Graham Number₹984.76
Key Metrics
Face Value
₹10
About Venus Remedies Ltd
Healthcare · Pharmaceuticals
Venus Remedies Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹2,286.96 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 192.75 | 180.26 | 259.4 | 178.86 |
| ↳ QoQ Growth | - | -6.5% | +43.9% | -31.0% |
| Expenses | 167.96 | 149.3 | 202.73 | 151.44 |
| Operating Profit | 24.79 | 30.96 | 56.67 | 27.42 |
| OPM % | 12.86% | 17.18% | 21.85% | 15.33% |
| Other Income | 1.71 | 2.52 | 4.95 | 2.62 |
| Interest | 0.01 | 0.01 | 0.01 | 0 |
| Depreciation | 6.17 | 6.56 | 6.75 | 6.77 |
| EBITDA | 30.96 | 37.52 | 63.42 | 34.19 |
| EBITDA Margin % | 16.06% | 20.81% | 24.45% | 19.12% |
| Profit Before Tax | 26.49 | 33.47 | 61.61 | 30.04 |
| Tax % | 24.01% | 23.57% | 22.9% | 23.54% |
| Net Profit | 20.13 | 25.58 | 47.5 | 22.97 |
| ↳ QoQ Growth | - | +27.1% | +85.7% | -51.6% |
| EPS | 15.06 | 19.14 | 35.53 | 17.18 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 13.367 | 13.37 |
| Reserves | 547.5825 | 650.38 |
| Borrowings | 1.69 | 12.41 |
| Other Liabilities | 153.08 | 177.54 |
| Total Liabilities | 715.7215 | 853.7 |
| Fixed Assets | 229.42 | 137.62 |
| CWIP | 26.3901 | 51.36 |
| Investments | 84.1 | 237.62 |
| Other Assets | 375.81 | 427.1 |
| Total Assets | 715.7215 | 853.7 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | 86.4421 | 155.7719 |
| Cash from Investing Activity | -76.2477 | -181.5689 |
| Cash from Financing Activity | -1.0192 | -3.1153 |
| Net Cash Flow | 9.1752 | -28.9123 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 41.76% | 41.76% | 41.76% | 41.76% |
| FIIs % | 1.86% | 2.26% | 2.8% | 2.92% |
| DIIs % | 0.75% | 1.03% | 1.2% | 0.89% |
| Public % | 45.3% | 45.16% | 44.39% | 44.31% |
| No. of Shareholders | 17,725 | 18,606 | 18,403 | 21,905 |
Major Shareholders (>1%)
- Sunev Pharma Solutions Pvt LtdPromoter and Promoter Group17.21%
- Pawan ChaudharyPromoter and Promoter Group12.82%
- Manu ChaudharyPromoter and Promoter Group11.73%
- Tikri Partners LlpPublic Shareholding1.97%
As of 2026-06-30View all shareholders →